Anaconda Biomed Appoints Trent Reutiman as CEO

January 7, 2025—Anaconda Biomed S.L. announced that it named Trent Reutiman its new CEO. The company’s previous CEO Francois Salmon will now serve as Anaconda’s Board Chairman. Anaconda, a developer of thrombectomy systems for treating ischemic stroke is headquartered in Barcelona, Spain.

Anaconda stated that Reutiman, who is based in California’s San Francisco Bay Area, will establish a new footprint for the company in the United States as it works toward regulatory approval of its ANA5 advanced neurovascular access device.

According to Anaconda, Reutiman has over 25 years of experience in executive, financial, market development, and sales operation leadership with an extensive focus in vascular technologies. He was the CEO of Mercator MedSystems Inc., VP of global commercial operations for Idev, and served in leadership roles at Rox Medical, OmniSonics Medical Technologies, and Rita Medical Systems.

The company’s ANA funnel catheter technology is designed to improve neurovascular interventions by enhancing the capabilities of existing and forthcoming intravascular neuro devices (ie, stent retriever devices). The ANA device comprises a radiopaque braid covered with a polymeric coating to enable local flow arrest. The catheter is currently an investigational device and is not available for sale in the United States or the European Union, advised the company.

In July 2024, the company announced it received conditional investigational device exemption approval from the FDA to begin the ATHENA study of the ANA funnel catheter.

“With its ANA funnel catheter technology, Anaconda Biomed has the potential to deliver a meaningful improvement in first-pass reperfusion outcomes, the latest standard in mechanical thrombectomy procedures for ischemic stroke,” commented Reutiman in the press release. “The company’s ATHENA study is designed to demonstrate clinically meaningful changes for ischemic stroke patients through arrested flow and more secure clot retrieval.”

Reutiman continued, “I am honored to join the company to build on its successes to date and look forward to working closely with Francois, the board, the talented Anaconda team, and all our study partners to bring this new technology to clinicians and patients in the United States and worldwide.”

Salmon added, “Trent is joining Anaconda at a pivotal time as we advance our clinical program and build evidence supporting FDA approval of the ANA funnel catheter in the United States. On behalf of myself and the rest of the board, we welcome his leadership and contributions moving forward.”